Report cover image

Next-Generation-Sequencing for Non-Invasive Prenatal Testing (NGS-NIPT) in China

Published Jun 29, 2016
Length 37 Pages
SKU # KLI15042533

Description

The Market for Next-Generation-Sequencing Neonatal Testing (NGS-NIPT) in China

Next Generation NIPT Sequencing in China estimates the revenues for non-invasive prenatal testing in this emerging market, and generally analyzes the role of next generation sequencing (NGS) in the country. Estimates in this report include revenues for non-invasive prenatal testing using sequencing in China, projections to 2020, market share. Institutions performing NGS and key equipment manufacturers and service providers are discussed.

This report was created as a cooperative project between Kalorama Information and The Freedonia Group, with staff from Freedonia’s Beijing office completing primary and secondary research.

Table of Contents

37 Pages
    • Scope and Methodology
    • Major Findings of The Report
    • China in Perspective
    • Population Trends and Demographics
    • Growing Chinese Hospital Sector
    • Intellectual Property Issues
    • Higher Out of Pocket Spending in China
    • Healthcare Reform
    • Disease Costs
    • Sequencing Introduction
    • Technologies Used for Newborn Screening
    • Introduction
    • Hospital Use of NGS
    • Major Competitors
    • Chinese NGS NIPT Market
    • Annoroad
    • Amoy Diagnostics Co., LTD
    • Berry Genomics Co. Ltd
    • Beijing Genomics Institute (BGI)
    • CapitalBio Corporation
    • Novogene
    • Daan Gene Co., Ltd.
    • Shanghai Kehua Bio engineering
    • Zhejiang Dian Diagnostics
    • Wuxi AppTec Co. LTD.
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.